Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer

PURPOSE: CALGB 40601 assessed whether dual versus single human epidermal growth factor receptor 2 (HER2) –targeting drugs added to neoadjuvant chemotherapy increased pathologic complete response (pCR). Here, we report relapse-free survival (RFS), overall survival (OS), and gene expression signatures...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Fernandez-Martinez, Aranzazu, Krop, Ian E., Hillman, David W., Polley, Mei-Yin, Parker, Joel S., Huebner, Lucas, Hoadley, Katherine A., Shepherd, Jonathan, Tolaney, Sara, Henry, N. Lynn, Dang, Chau, Harris, Lyndsay, Berry, Donald, Hahn, Olwen, Hudis, Clifford, Winer, Eric, Partridge, Ann, Perou, Charles M., Carey, Lisa A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2020
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7723687/
https://ncbi.nlm.nih.gov/pubmed/33095682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01276
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados